All randomized, controlled clinical trials of aliskiren (evidence level 2) were included for analysis of efficacy with the selected outcomes of blood pressure lowering, tolerability, and adherence; all other publications were excluded.
Other clinical measures include the impact (either positive or negative) of Cycloset™ on HbA1c, fasting plasma glucose, weight, triglycerides lipids, blood pressure and patient tolerability after six months of therapy.
The objective of this article is to review the available evidence, limited to phase II trials and pilot trials, for the use of aliskiren in patients with hypertension, evaluating its effects on available measured outcomes including blood pressure, adherence, and tolerability.
The most important reason to combine two or more classes of antihypertensive drug is to obtain enhanced blood pressure control with good tolerability.
To evaluate the efficacy, tolerability, and blood pressure (BP) lowering effect of extended release metoprolol succinate (ER metoprolol) in children 6 to 16 years of age with established hypertension.
Standard anal physiology tests including resting anal pressure, squeeze pressure, rectal volume tolerability, anal sensitivity, pudendal nerve motor latency, and endoanal ultrasound were performed at baseline and results were within the normal range previously published from our unit [ 18].
A1C, fasting plasma glucose (FPG), body weight, blood pressure, fasting lipids, safety, and tolerability were assessed.
This safety study compared the GI tolerability, the blood pressure (BP) profile and the incidence of oedema with lumiracoxib and rofecoxib in the treatment of OA.
As with other antihypertensive agents in geriatric patients, it is reasonable to start candesartan at a low dose and titrate according to tolerability and blood pressure goals.
However, differences in the mechanisms of action and pharmacodynamics/pharmacokinetics, between and within these classes, can result in important differences in fasting plasma glucose (FPG), postprandial glucose (PPG), body weight, β-cell function, blood pressure (BP), and safety and tolerability [ 44], as found in randomized head-to-head clinical trials (Tables 2, 3, 4, 5, 6, 7, 8, 9 [ 12– 33]).
